An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 (NCT04168957) | Clinical Trial Compass
TerminatedPhase 1
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Stopped: No need to complete the overall survival (OS) follow-up as the sample size was too small to interpret OS.
Taiwan11 participantsStarted 2017-10-25
Plain-language summary
KX-ORAX-008 is an extension study of patients who completed KX-ORAX-007 without disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and who wish to continue Oraxol treatment.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Breast cancer patients who have completed Study KX-ORAX-007 without disease progression at Week 16, who wish to continue Oraxol treatment.
✓. Signed written informed consent.
✓. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days.
✓. Patients must be postmenopausal (\>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.
Exclusion criteria
✕. Have not recovered from unacceptable toxicity associated with previous Oraxol treatment in KX-ORAX-007.
✕. Are currently receiving other medications intended for the treatment of their malignancy.
✕. Women who are pregnant or breastfeeding.
✕. Taking any following prohibited medications:
✕. Use of warfarin. Patients receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.
✕. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements.
What they're measuring
1
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: From screening until final visit (within 72 hours prior to Day 21 of Study Period 2, preferably before the participant receives any additional chemotherapy)